anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We propose to investigate the anti-anxiety activity of Chamomile. Among the many uses of Chamomile, its use as an anti-anxiety herb is universal. Despite its widespread use and acceptance, there have been no studies evaluating the safety and anti-anxiety efficacy of Chamomile in human subjects. Given this lack of controlled clinical data, we propose a pilot study of Chamomile safety and efficacy in mild anxiety, and propose using the data as a basis for statistically powering a future R01 application. We will ask: Is Chamomile a safe and effective alternative treatment for Generalized Anxiety Disorder (GAD)? To do this, 60 patients with a diagnosis of mild to moderate GAD will receive double-blind treatment for 8 weeks with either (i) Chamomile extract, or (ii) placebo. We hypothesize that Chamomile will have a superior anti-anxiety efficacy compared to placebo, and a comparable safety profile to placebo.
Frailty is an age-related syndrome that drives multiple physiological system impairments in some older adults, and its pathophysiological mechanisms remain unclear. We evaluated whether frailty-related biological processes could impair stem cell compartments, specifically the renal stem compartment, given that kidney dysfunctions are frequent in frailty. A well-characterized in vitro nephrosphere model of human adult renal stem/progenitor cells has been instrumental to and was appropriate for verifying this hypothesis in our current research. Evaluating the effects of plasma from older individuals with frailty (frail plasma) on allogeneic renal stem/progenitor cells, we showed significant functional impairment and nuclear DNA damage in the treated cells of the renal stem compartment. The analysis of the frail plasma revealed mitochondrial functional impairment associated with the activation of oxidative stress and a unique inflammatory mediator profile in frail individuals. In addition, the plasma of frail subjects also contained the highest percentage of DNA-damaged autologous circulating hematopoietic progenitor/stem cells. The integration of both molecular and functional data obtained allowed us to discern patterns associated with frailty status, irrespective of the comorbidities present in the frail individuals. The data obtained converged toward biological conditions that in frailty caused renal and hematopoietic impairment of stem cells, highlighting the possibility of concomitant exhaustion of several stem compartments.
BACKGROUND: Endovascular thrombectomy (EVT) is a standard treatment for acute ischemic stroke (AIS) with large vessel occlusion. Hypertension and increased blood pressure variability within the first 24 h after successful reperfusion are related to a higher risk of symptomatic intracerebral hemorrhage and higher mortality. AIS patients might suffer from ischemia-reperfusion injury following reperfusion, especially within 24 h. Dexmedetomidine (DEX), a sedative commonly used in EVT, can stabilize hemodynamics by inhibiting the sympathetic nervous system and alleviate ischemia-reperfusion injury through anti-inflammatory and antioxidative properties. Postoperative prolonged sedation for 24 h with DEX might be a potential pharmacological approach to improve long-term prognosis after EVT.
METHODS: This single-center, open-label, prospective, randomized controlled trial will include 368 patients. The ethics committee has approved the protocol. After successful reperfusion (modified thrombolysis in cerebral infarction scores 2b-3, indicating reperfusion of at least 50% of the affected vascular territory), participants are randomly assigned to the intervention or control group. In the intervention group, participants will receive 0.1~1.0 μg/kg/h DEX for 24 h. In the control group, participants will receive an equal dose of saline for 24 h. The primary outcome is the functional outcome at 90 days, measured with the categorical scale of the modified Rankin Scale, ranging from 0 (no symptoms) to 6 (death). The secondary outcome includes (1) the changes in stroke severity between admission and 24 h and 7 days after EVT, measured by the National Institute of Health Stroke Scale (ranging from 0 to 42, with higher scores indicating greater severity); (2) the changes in ischemic penumbra volume/infarct volume between admission and 7 days after EVT, measured by neuroimaging scan; (3) the length of ICU/hospital stay; and (4) adverse events and the all-cause mortality rate at 90 days.
DISCUSSION: This randomized clinical trial is expected to verify the hypothesis that postoperative prolonged sedation with DEX after successful reperfusion may promote the long-term prognosis of patients with AIS and may reduce the related socio-economic burden.
TRIAL REGISTRATION: ClinicalTrials.gov NCT04916197. Prospectively registered on 7 June 2021.
There are disclosed methods and apparatus for monitoring the status of a condition of an animal. A condition is selected for monitoring. A monitoring material is selected for introduction into the animal. A method of introducing the monitoring material into the animal is selected. At least one site on the animal is selected for introducing the monitoring material. The monitoring material is introduced into the animal at the selected sites. As a result of the introduction of the monitoring material, a visually ascertainable indication of a status of a condition of the animal appears on the animal's skin. The indication may be observed to thereby visually ascertain the status of the condition.
Participants will receive Test Product A (single dose of 2 caplets \[Combination caplet with loperamide hydrocloride \[HCl\] 2 milligram \[mg\] + simethicone 125 mg\]) orally on Day 1 followed by Reference Product B (single dose of 2 Imodium Express tablets-lyophilizate \[2\*2 mg loperamide HCl\] + 6 Espumisan capsules \[6\*40 mg simethicone\]) orally on Day 13. A washout period of at least 7 days will be maintained between each treatment.
Abnormal Transmembrane protein 9 (TMEM9) expression has been identified in various human tumors. However, the prognostic potential and mechanistic role of TMEM9 in lung adenocarcinoma (LUAD) remain unclear. Here, we first found a significant upregulation of TMEM9 in LUAD tissues, and TMEM9 expression was positively correlated with microvessel density (MVD), T stage, and clinical stage. Survival analysis demonstrated TMEM9 was an independent indicator of poor prognosis in LUAD patients. In addition, downregulation of TMEM9 suppressed tumor growth and metastasis in vitro and in vivo models, and reduced HUVEC proliferation, migration, and tube formation in a cancer cell/HUVEC coculture model. Furthermore, TMEM9 upregulated VEGF expression, and VEGF-neutralizing antibodies reversed HUVEC angiogenesis and cancer cell migration ability caused by overexpression of TMEM9. In contrast, recombinant VEGF (rVEGF) abolished the inhibitory effect of TMEM9-knockdown LUAD cells on HUVEC angiogenesis and tumor cell migration. Moreover, we showed that TMEM9 upregulated VEGF expression by activating the mitogen-activated protein kinase/extracellular signal-regulated kinase/STAT3 (MEK/ERK/STAT3) pathway. Together, our study provides mechanistic insights into the role of TMEM9 in LUAD and highlights the potential of targeting the TMEM9/MEK/ERK/STAT3/VEGF pathway as a novel therapy for preventing LUAD progression.
The invention provides a medicament for treating ulcerative colitis and relates to the medicament for treating colitis. The medicament is prepared by selecting the following raw materials by mass: 3 to 5g of synthetic bovine bezoar, 1.5 to 2.5g of borneol, 19 to 27g of pearl, 19 to 27g of ivory flakes, 88 to 100g of natural indigo and 13 to 19g of wall spider, grinding the raw materials are into powder, passing the power through a screen, and mixing the power to form mixed powder A; mixing 40,000 to 80,000 units of gentamicin and 30 to 50 ml of metronidazole solution to form gentamicin-metronidazole solution, and dissolving 1 percent of the mixed powder A into the gentamicin-metronidazole solution. The medicament has the advantages that: the medicament treats the ulcerative colitis and proctitis by a clysis method. The medicament can directly reach affected parts, can improve local blood concentration in intestines, avoids first-pass effect of liver, prevents or reduces damage of medicament to the liver and damage of digestive juice of stomach and intestines, and digestive enzyme to the medicament, and gives full play to availability of the medicament. The medicament also has the advantages of addressing of symptoms and root causes, rapid medicinal effect, safety, reliability and good curative effect. 156 clinical tests show that the effective rate of the medicament reaches 100 percent.
PROBLEM TO BE SOLVED: To provide products such as paper, cloth, non-woven fabric, solid particles, lotion, gas and liquid for securing plant raw materials and a variety of plants synthetic powder indispensable for achieving a purpose for filling a space whose internal capacity is not smaller than 500mwith a variety of plant particles, and generating plant molecules and atoms.SOLUTION: In order to secure a variety of the plant particles, multi-kind/multi-type plants are crushed into sizes of nano units not larger than 3 cm, and the multi-kind plants synthetic powder 10 is secured. The powder is kneaded and fermented into each product, evaporated into mixed air 8, and mixed into a mixed liquid 7. Each product is heated, exposed to air, optically synthesized, and wave-moved by a far-inflared ray. The powder is separated into a unit molecule by plant body constituent molecules, and a large amount of the plant molecules are floated in the space whose in-room capacity is not larger than 500m. Thus, a person purposing beautification can expect the improvement of a physical constitution. For a means for improving and eliminating the disease of a modern disease patient, the plant molecules are made to enter a physical body by respiration.
This invention provides mutagenized interleukin 13 molecules that show improved specificity for the restricted (IL4 independent) IL13 receptor and reduced cross reactivity with the IL4/IL4 shared receptor. The mutagenized IL13 molecules include one or more mutations in a domain that interacts with the 140 kDa hIL4R.beta. or the hIL13R.alpha.1 subunit. These mutagenized IL13 molecules provide effective targeting moieties in chimeric molecules (e.g.  fusion proteins) that specifically deliver effector molecules (e.g.  cytotoxins) to cells overexpressing IL13 receptors (e.g. cancer cells such as gliomas).
Fentanyl citrate (equivalent to 80 mcg fentanyl)administered over 20 minutes by IV infusion every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
This study will evaluate the acceptability and effectiveness of a strength-based intervention (Kessler Foundation Strength Identification and Expression; KF-STRIDE) that can enhance job interview skills and employment. Despite possessing employable talents, the core social deficits of transition age youth with autism spectrum disorder (TAY-ASD) make it difficult for this group to articulate their individual strengths. This inability to identify and express one's strengths to a potential employer can negatively affect interview performance and lead to difficulty with job obtainment. Thus, the current proposal will examine the effectiveness (Aim 1), acceptability, usability, and feasibility (Aim 2) of a novel strength-based intervention, KF-STRIDE, which is designed to enhance the ability of TAY-ASD to identify personal strengths and effectively discuss them. The goals of the current study are to evaluate the preliminary effectiveness and feasibility of KF-STRIDE in an 8-week randomized controlled trial comparing the intervention to services as usual (SAU). The study will be performed at two private therapeutic schools. Compared to a SAU group, we hypothesize that the KF-STRIDE group will: a) improve the ability to identify strengths (Hypothesis 1), b) improve the ability to express strengths (Hypothesis 2), c) improve other job interview skills (Hypothesis 3) and finally c) improve ability to obtain employment 6-months following the intervention (Hypothesis 4). In this way, the current study is in line with the NIMH's experimental therapeutics model, as we will examine whether the intervention improves employment, as well as identify potential mechanistic targets that could affect outcome. In Aim 2, we will also monitor fidelity, acceptability, usability, and feasibility of the strength-based intervention. The long-term goal of the current research is to collect pilot data that will lead to fully-powered effectiveness and implementation evaluations of KF-STRIDE in other community settings.
Obligate biotrophs depend on living hosts for nutrient acquisition to complete their life cycle, yet the mechanisms by which hosts restrict nutrient availability to pathogens remain largely unknown. The fungal pathogen Sporisorium reilianum infects maize seedlings and causes head smut disease in inflorescences at maturity, while a cell wall-associated kinase, ZmWAK, provides quantitative resistance against it. In this study, we demonstrate that S. reilianum can rapidly activate ZmWAK kinase activity, which is sustained by the 407th threonine residue in the juxtamembrane domain, enabling it to interact with and phosphorylate ZmSnRK1α2, a conserved sucrose non-fermenting-related kinase α subunit. The activated ZmSnRK1α2 translocates from the cytoplasm to the nucleus, where it phosphorylates and destabilizes the transcription factor ZmWRKY53. The reduced ZmWRKY53 abundance leads to the downregulation of genes involved in transmembrane transport and carbohydrate metabolism, resulting in nutrient starvation for S. reilianum in the apoplast. Collectively, our study uncovers a WAK-SnRK1α2-WRKY53 signaling module in maize that conveys phosphorylation cascades from the plasma membrane to the nucleus to confer plant resistance against head smut in maize, offering new insights and potential targets for crop disease management.
In a prospective, randomized and blinded study robotic naïve (urology (n = 12), surgery (n = 12) and gynecology (n = 12)) residents (n = 36) from the KU Leuven and University of Gent residency training programs will be randomized (in equal discipline numbers) to Traditional Halstedian apprenticeship type training or proficiency based progression (PBP) training to learn to perform a vesico-urethral anastomosis (VUA) on a chicken model. Both groups will receive the same e-learning (on how to perform the VUA on the chicken model) and skills laboratory robotic training curriculum. The PBP trained group will however be required to demonstrate quantitively defined proficiency benchmarks for training progression (i.e., from e-learning to the skills lab). The PBP group will also have a defined benchmark to demonstrate before training is deemed completed. The Traditional trained group will train in the same skills laboratory for a case-matched period of time as the PBP group, with the same level of supervising faculty proctors and using the same training resources but with no proficiency benchmarks or metric-based feedback. Both groups will be required to perform a VUA on the chicken model before skills training proper and at the end of training. Investigators will be trained in pairs to assess VUA performance from a pre-defined set of explicitly defined binary metric events reliably (inter-rater reliability \> 0.8). They will also be blinded as to the identity of the trainee performing the procedure, how they were trained (i.e., group) and procedure order.

H1 It is hypothesized that implementation of PBP training in teaching the robotic suturing of VUA leads to better surgical training outcomes (i.e., lower number of performance errors) when compared to Halsted's method.
An active coloring concentrate can be prepared from the juice of cranberry and other fruits or vegetables by treating juice or homogenate with an appropriate binding matrix. Assorted ion exchange resins such as cholestytamine are effective binding matrices, but the currently preferred material is a food grade of cross-linked polyvinylpyrollidone. When appropriate binding matrices are used to concentrate active materials from cranberry, a colored solid is produced. This substance shows significant antibacterial and anti-viral properties. It can be readily consumed as a therapeutic or nutraceutical, used as a coloring agent, or it can be used topically. An additional advantage of the present method is that significant amounts of active concentrate can be produced from cranberrry presscake which is normally a waste material.
The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to novel uses of muscle-derived progenitor cells for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the novel use of MDCs for the increase of skeletal muscle mass in athletes or other organisms in need of greater than average skeletal muscle mass.
An auxiliary surface EMG will be recorded via ordinary skin electrodes at the diaphragm, and intercostal and rectus abdominis muscles. The degree of neuromuscular blockade is continuously measured by accelerometry of the adductor pollicis muscle with ulnar nerve stimulation (TOF-watch SX®). Anesthesia is induced with propofol and remifentanil. Manually assisted ventilation with an air/oxygen mixture of 40% oxygen is started as soon as patients are becoming apnoeic. Train-of-four (TOF) monitoring starts after the induction of anesthesia (before rocuronium administration) and continues until awakening. The investigators will insert a 16 Fr. nasogastric catheter which allows electrical activity of the diaphragm (Edi) registration (NAVA, Maquet, Solna, Sweden). After baseline measurements, 0.6 mg/kg rocuronium is injected. After tracheal intubation, subjects will be ventilated by a standard ventilation mode (tidal volume 7 ml/kg, frequency of 12 breaths per minute, inspired oxygen fraction of 30%), with end-tidal PCO2 targets of 30-35 mmHg and a PEEP of 5 cmH2O. SpO2 values will be maintained at ≥98%. Spontaneous recovery is allowed to progress until the re-appearance of the second twitch of the TOF. The volunteers will then receive either sugammadex 2mg/kg or neostigmine 50µg/kg + glycopyrrolate 10µg/kg (using the commercially available 5:1 co-formulation) or neostigmine 50µg/kg followed 3 minutes later by administration of sugammadex 2mg/kg. At the onset of spontaneous respiration, an arterial blood gas sample will be drawn. NAVA catheter positioning will be confirmed using the 'Edi catheter positioning' tool as soon as a signal is received. A second arterial blood gas sample will be drawn at the moment of awakening.

Diaphragm electromyographic activity (Edi, obtained from the NAVA catheter), airway pressure and flow are acquired at 100 Hz from the ventilator via an interface connected to a computer using commercially available software (Maquet Critical Care, Solna, Sweden). The auxiliary surface EMG will be recorded with a dedicated device (Dipha16, InBiolab, Groningen, The Netherlands) at the diaphragm, and intercostal and rectus abdominis muscles. All data will be stored and later analysed.
Neuro-ophthalmic evaluation is a crucial component of the diagnostic and prognostic assessment of pituitary disease and compressive chiasmopathy, and can inform the timing of vision-restoring tumour resection surgery. The most common disease affecting the pituitary with neuro-ophthalmic implications are pituitary adenomas. Neuro-ophthalmic manifestations include decreased vision, abnormal colour vision and impaired visual field or diplopia. The recognition of these syndromes is critical to achieve early diagnosis and treatment and to improve prognosis. The pattern of vision loss in chiasmal compression is determined by the anatomical relationship between the pituitary lesion and optic chiasm, and potential visual field defects include bitemporal deficits, junctional scotomas, monocular cecocentral defects, and incongruous homonymous hemianopias. Rarer neuro-ophthalmic manifestations of pituitary disease include ophthalmoplegia, nystagmus, and obstructive hydrocephalus. There is growing evidence that demonstrates the strong diagnostic utility of optical coherence tomography (OCT) parameters in detecting the presence of compressive chiasmopathy, as well as the prognostic ability to predict the rate and degree of visual recovery following decompression surgery. Long-term neuro-ophthalmic monitoring is critical for detecting delayed vision loss following resection surgery, which may represent tumour recurrence or secondary complications.
FIELD: medicine, anesthesiology. SUBSTANCE: method involves premedication with atropine and seduxen, denitrogenization with oxygen, prenarcosis, myoplegia, intubation, xenon feeding and anesthesia carrying out at small gas flow. Denitrogenization and mechanical ventilation of lungs (MVL) were carried out by semiopen contour at gas rate 6-8 and 6-8 l/min, respectively. After change for open contour content of oxygen in respiratory sac is 500 ml, not above. Xenon is fed at volume 1.3 vital capaciti of lungs (VCL) for 1.5-2 min and the following anesthesia is carried out at oxygen concentration 30%, not less. Method ensures xenon consumption decrease by 3-4-fold, narcosis onset is decreased to 4-5 min. EFFECT: enhanced effectiveness of method, decreased cost and xenon consumption.
The placebo arm consisted of 3 placebo capsules to match AZD7268 capsules dosed orally in the morning and evening. In addition, 2 placebos to match encapsulated escitalopram tablets were dosed orally in the morning only.
Patients with targetable disease-causing genetic alterations will be evaluated on a case by case basis. The research study will utilize biospecimens to determine if an individualized therapeutic may be developed as a possible treatment option. If an individualized therapeutic drug can be developed, a future IND FDA application (n=1) will be filed.
1. SSRIs and SNRIs, including escitalopram oxalate, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to the risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to SSRIs and SNRIs use have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. 



Patients should be cautioned about the risk of bleeding associated with the concomitant use of escitalopram oxalate and NSAIDs, aspirin, or other drugs that affect coagulation.